| scholarly article | Q13442814 |
| P50 | author | Martín E Fernández-Zapico | Q90465732 |
| P2093 | author name string | Luciana L Almada | |
| Anne J Novak | |||
| Stephen M Ansell | |||
| Thomas E Witzig | |||
| Lucy S Hodge | |||
| Deanna M Grote | |||
| Sherine F Elsawa | |||
| Steven C Ziesmer | |||
| P2860 | cites work | Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activation | Q24319880 |
| Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors | Q28235378 | ||
| Gene-expression profiling of Waldenstrom macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma | Q28248800 | ||
| Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components | Q28257845 | ||
| PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo | Q28609356 | ||
| Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli | Q29618769 | ||
| Interleukin 6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. | Q31983538 | ||
| GLI2 transcription factor mediates cytokine cross-talk in the tumor microenvironment. | Q35065222 | ||
| Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia | Q35116840 | ||
| Hyperviscosity syndrome in plasma cell dyscrasias | Q35590486 | ||
| Bone marrow microenvironment and the identification of new targets for myeloma therapy | Q36162703 | ||
| Long-term culture of human bone marrow cells | Q36402575 | ||
| Mechanisms of disease: regulation of RANTES (CCL5) in renal disease | Q36745404 | ||
| Cytokines in the microenvironment of Waldenström's macroglobulinemia. | Q36783925 | ||
| Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment | Q36839270 | ||
| Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications | Q37201984 | ||
| The microenvironment in mature B-cell malignancies: a target for new treatment strategies | Q37563816 | ||
| Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer | Q37820802 | ||
| Blocking interleukin-1β in acute and chronic autoinflammatory diseases | Q37821071 | ||
| Inflammatory signals regulate hematopoietic stem cells | Q37828295 | ||
| Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage | Q37845554 | ||
| Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. | Q40087182 | ||
| Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells | Q40223980 | ||
| B-lymphocyte stimulator (BLyS) stimulates immunoglobulin production and malignant B-cell growth in Waldenstrom macroglobulinemia | Q40348403 | ||
| Cytokine-induced myeloid differentiation is dependent on activation of the MEK/ERK pathway | Q40373169 | ||
| Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells | Q40490939 | ||
| Serum levels of IL-6 and its soluble receptor (sIL-6R) in Waldenström's macroglobulinemia. | Q40728277 | ||
| Transcriptional regulation of the interleukin-6 gene in mesangial cells | Q40942132 | ||
| Involvement of Stat3 in interleukin-6-induced IgM production in a human B-cell line | Q41121963 | ||
| Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines | Q41208928 | ||
| Development and characterization of a human marrow stromal cell line that enhances osteoclast-like cell formation | Q41357481 | ||
| Immunoglobulin secretion and phosphorylation of common proteins are induced by IL-2, IL-4, and IL-6 in the factor responsive human B cell line, SKW6.4. | Q41508886 | ||
| Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. | Q42520173 | ||
| Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications | Q43830963 | ||
| Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target | Q46202182 | ||
| Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells | Q48000642 | ||
| Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. | Q52196589 | ||
| Extended rituximab therapy in Waldenström's macroglobulinemia. | Q53876960 | ||
| Serum concentrations of angiogenic cytokines in Waldenstrom macroglobulinaemia: the ratio of angiopoietin-1 to angiopoietin-2 and angiogenin correlate with disease severity | Q57904812 | ||
| Abnormal bone remodelling and increased levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) in Waldenstrom macroglobulinaemia | Q57904835 | ||
| Treatment of Waldenstrom's Macroglobulinemia with Rituximab: Prognostic Factors for Response and Progression | Q57904975 | ||
| Regulation of IL-6 and IL-8 expression in rheumatoid arthritis synovial fibroblasts: the dominant role for NF-kappa B but not C/EBP beta or c-Jun | Q64380214 | ||
| Smouldering Waldenstrom's macroglobulinemia: Factors predicting evolution to symptomatic disease | Q73329249 | ||
| Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity | Q73374303 | ||
| Cell-specific differences in the regulation of IL-6 expression by PMA | Q77994869 | ||
| P433 | issue | 20 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 5540-5549 | |
| P577 | publication date | 2011-09-14 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Comprehensive analysis of tumor microenvironment cytokines in Waldenstrom macroglobulinemia identifies CCL5 as a novel modulator of IL-6 activity | |
| P478 | volume | 118 |
| Q37621361 | Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma. |
| Q35184435 | Antagonism of cannabinoid receptor 2 pathway suppresses IL-6-induced immunoglobulin IgM secretion |
| Q43272252 | CXCL13 levels are elevated in patients with Waldenström macroglobulinemia, and are predictive of major response to ibrutinib. |
| Q37058267 | Cancer prevention and therapy through the modulation of the tumor microenvironment |
| Q37074275 | Candidate genes of Waldenström's macroglobulinemia: current evidence and research. |
| Q36454593 | Cisplatin-induced mesenchymal stromal cells-mediated mechanism contributing to decreased antitumor effect in breast cancer cells |
| Q36384484 | Comprehensive serum cytokine analysis identifies IL-1RA and soluble IL-2Rα as predictors of event-free survival in T-cell lymphoma |
| Q41956333 | Constitutive activation of STAT5A and STAT5B regulates IgM secretion in Waldenstrom's macroglobulinemia |
| Q37151653 | Critical role of the WASF3 gene in JAK2/STAT3 regulation of cancer cell motility |
| Q88888761 | Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review |
| Q51026913 | Elevated RANTES level is associated with metabolic syndrome and correlated with activated platelets associated markers in healthy younger men. |
| Q34626318 | Elevated soluble IL-2Rα, IL-8, and MIP-1β levels are associated with inferior outcome and are independent of MIPI score in patients with mantle cell lymphoma |
| Q27021855 | Factors regulating immunoglobulin production by normal and disease-associated plasma cells |
| Q57287569 | Loss of TNFAIP3 enhances MYD88-driven signaling in non-Hodgkin lymphoma |
| Q28817598 | Mature IgM-expressing plasma cells sense antigen and develop competence for cytokine production upon antigenic challenge |
| Q34012393 | Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer. |
| Q36031506 | Modulation of the IL-6 Receptor α Underlies GLI2-Mediated Regulation of Ig Secretion in Waldenström Macroglobulinemia Cells. |
| Q38024773 | Molecular pathogenesis of Waldenstrom's macroglobulinemia. |
| Q48210066 | Novel Molecular Mechanism of Regulation of CD40 Ligand by the Transcription Factor GLI2. |
| Q38167433 | Novel treatment options for Waldenström macroglobulinemia |
| Q33966915 | Selective androgen receptor modulators (SARMs) negatively regulate triple-negative breast cancer growth and epithelial:mesenchymal stem cell signaling |
| Q38763837 | Siltuximab and hematologic malignancies. A focus in non Hodgkin lymphoma |
| Q36589648 | Single-cell protein secretomic signatures as potential correlates to tumor cell lineage evolution and cell-cell interaction |
| Q58786066 | Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia |
| Q41192923 | TCL1 expression patterns in Waldenström macroglobulinemia |
| Q64974549 | Targeting IL-6 receptor reduces IgM levels and tumor growth in Waldenström macroglobulinemia. |
| Q27028214 | The bone marrow microenvironment in Waldenström macroglobulinemia |
| Q37490002 | Transgenic mouse model of IgM+ lymphoproliferative disease mimicking Waldenström macroglobulinemia. |
| Q38104808 | Waldenström macroglobulinaemia: the key questions. |
| Q38176969 | Waldenström macroglobulinemia: from biology to treatment |
Search more.